Írland - enska - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - adenosine - solution for injection in pre-filled syringe - 3 milligram(s)/millilitre - other cardiac preparations; adenosine

Malta - enska - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - adenosine - solution for injection - adenosine 3 mg - cardiac therapy

Malta - enska - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - adenosine - solution for infusion - adenosine 3 mg - cardiac therapy

Bandaríkin - enska - NLM (National Library of Medicine)

a-s medication solutions - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning art

Írland - enska - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - adenosine - solution for injection - 3 milligram(s)/millilitre - other cardiac preparations; adenosine

Írland - enska - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - adenosine - solution for infusion - 30 milligram/ 10 millilitre - other cardiac preparations; adenosine

Írland - enska - HPRA (Health Products Regulatory Authority)

focus pharmaceuticals ltd - adenosine - solution for injection - 3 milligram(s)/millilitre - other cardiac preparations; adenosine

Bandaríkin - enska - NLM (National Library of Medicine)

astellas pharma us, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenocard (adenosine injection) is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenocard administration. it is important to be sure the adenocard solution actually reaches the systemic circulation (see dosage and administration). adenocard does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenocard administration. intravenous adenocard (adenosine injection) is contraindicated in:

Bandaríkin - enska - NLM (National Library of Medicine)

teva parenteral medicines, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine [see warnings and precautions (5.7)] animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine can cause fetal harm when administered to pregnant women, adenosine should be used during pregnancy only if clearly needed. it is not known whether adenosine is excreted

Írland - enska - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - adenosine - solution for injection - 3 mg/ml - other cardiac preparations